CTI BioPharma Announces Extension Of FDA Review Period For Pacritinib In Myelofibrosis With Severe Thrombocytopenia; Announces New PDUFA Date Of Feb. 28

Your email address will not be published. Required fields are marked *

Comment

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.